Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US OptionsDetailed Quotes
HALO250516P85000
- 0.00
- 0.000.00%
15min DelayClose Apr 28 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest85.00Strike Price0.00Turnover77.44%IV-40.33%PremiumMay 16, 2025Expiry Date24.43Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9829Delta0.0079Gamma2.48Leverage Ratio-0.0082Theta-0.0108Rho-2.43Eff Leverage0.0052Vega
Halozyme Therapeutics Newsroom
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $72
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target
Halozyme Therapeutics Analyst Ratings
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $67
Halozyme Therapeutics Analyst Ratings
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $78
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $78
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $75
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Raises Target Price to $60
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $72
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $67 to $78
Halozyme Therapeutics Price Target Raised to $72.00/Share From $70.00 by HC Wainwright & Co.
Halozyme Therapeutics Analyst Ratings
Morgan Stanley Initiates Halozyme Therapeutics(HALO.US) With Buy Rating, Announces Target Price $67
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $70
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $75
Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $77
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now